Results 21 to 30 of about 1,204 (125)

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation

Frontiers in Neurology
BackgroundThe prevalence of patients positive for muscle-specific kinase antibody (hereafter, MuSK-Ab) accounts for 5–8% of all myasthenia gravis (MG) cases.
Fangyi Shi, Fangyi Shi, Fangyi Shi, Jiaxin Chen, Jiaxin Chen, Jiaxin Chen, Li Feng, Li Feng, Li Feng, Rong Lai, Rong Lai, Rong Lai, Hongyan Zhou, Hongyan Zhou, Hongyan Zhou, Xunsha Sun, Xunsha Sun, Xunsha Sun, Cunzhou Shen, Cunzhou Shen, Cunzhou Shen, Jiezhen Feng, Jiezhen Feng, Jiezhen Feng, Huiyu Feng, Huiyu Feng, Huiyu Feng, Haiyan Wang, Haiyan Wang, Haiyan Wang   +29 more
doaj   +1 more source

Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report

BMC Neurology
Background Generalized myasthenia gravis (gMG) can be managed with acetylcholinesterase inhibitors (AChEis; e.g., pyridostigmine), corticosteroids, other immunosuppressive drugs (e.g., tacrolimus), and their combinations. Intravenous immunoglobulin (IVIg)
Hiroya Ohara, Naoya Kikutsuji, Naohiko Iguchi, Masako Kinoshita   +3 more
doaj   +1 more source

Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler, Simon Lüdtke, Lena Dietze, Marie Schiffmann, Dominik Straube, Jan Ehrchen   +5 more
wiley   +1 more source

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial

Therapeutic Advances in Neurological Disorders
Summary What is this summary about? This is a plain language summary of an article published in The Lancet Neurology in 2024. The article describes the results of the ADHERE clinical study, which involved people with chronic inflammatory demyelinating ...
Jeffrey A. Allen, Luis Querol, Niraja Suresh, Anneleen Remmerie, Trevor Mole, Kelly McCoy, Lisa Butler, Benjamin van Hoorick, Satoshi Kuwabara, Pieter A. van Doorn, Richard A. Lewis   +10 more
doaj   +1 more source

Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report

BMC Neurology
Background Anti-NMDA receptor encephalitis is an autoimmune, antibody-mediated inflammatory disease of the brain characterized by the presence of IgG antibodies targeting the excitatory N-methyl-D-aspartate receptor (NMDAR).
Huasheng Huang, Yizhi Wei, Huihui Qin, Guangshun Han, Jie Li   +4 more
doaj   +1 more source

Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control

Biomedicines
Introduction: Myasthenia gravis (MG), an immune disorder affecting nerve-muscle transmission, often necessitates tailored therapies to alleviate longitudinal symptom fluctuations.
Shingo Konno, Takafumi Uchi, Hideo Kihara, Hideki Sugimoto   +3 more
doaj   +1 more source

Sequential and Concurrent C5 and Neonatal Fc Receptor Inhibition in Prolonged Myasthenic Crisis due to Advanced Invasive Thymoma‐Associated Myasthenia Gravis: A Case Report and Literature Review

Clinical and Experimental Neuroimmunology, Volume 17, Issue 4, November 2026.
ABSTRACT Thymoma‐associated myasthenia gravis (TAMG) is frequently refractory, particularly when complicated by myasthenic crisis in advanced invasive disease. Complement C5 inhibitors and neonatal Fc receptor (FcRn) inhibitors have expanded the treatment of acetylcholine receptor (AChR) antibody‐positive generalized myasthenia gravis; however, their ...
Yuta Kizuka, Yuriko Nakamura, Kensuke Okada, Yu Okubo, Kaoru Kaseda, Hirofumi Toyama, Keisuke Asakura, Atsuya Takeda, Jin Nakahara, Kei Ishizuchi   +9 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China

Annals of Clinical and Translational Neurology
Objective Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG ...
Sushan Luo, Qilong Jiang, Wenshuang Zeng, Qinzhou Wang, Zhangyu Zou, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jing Chen, Zhongyan Zhao, Shixiong Huang, Jianquan Shi, Ying Chen, Lei Du, Chong Yan, Jianying Xi, Jie Song, Chongbo Zhao, the Chinese Myasthenia Gravis Collaborating Group (CMGCG)   +22 more
doaj   +1 more source

Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy

Frontiers in Immunology
BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated polyneuropathy. Early and effective immunomodulatory treatment is essential to prevent long-term disability.
Yanping Ran, Wenlin Wu, Chi Hou, Haixia Zhu, Wenxiao Wu, Zongzong Chen, Xuexia Ma, Xiaolan Mo, Houliang Deng, Yuanyuan Gao, Xiaojing Li   +10 more
doaj   +1 more source